AGN 211745

Drug Profile

AGN 211745

Alternative Names: AGN-211745; AGN-745; Sirna 027

Latest Information Update: 16 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sirna Therapeutics
  • Developer Allergan
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 13 Feb 2007 Phase-II clinical trials in Age-related macular degeneration in USA (Intravitreous)
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 14 Aug 2006 Final results from a phase I clinical trial in patients with age-related macular degeneration have been added to the adverse events and Eye Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top